| MeSH term | MeSH ID | Detail |
|---|---|---|
| Breast Neoplasms | D001943 | 24 associated lipids |
| Lung Neoplasms | D008175 | 171 associated lipids |
| Pancreatic Neoplasms | D010190 | 77 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Mammary Neoplasms, Experimental | D008325 | 67 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
| Prostatic Neoplasms | D011471 | 126 associated lipids |
| Melanoma | D008545 | 69 associated lipids |
| Brain Diseases | D001927 | 27 associated lipids |
| Leukemia P388 | D007941 | 43 associated lipids |
MAYTANSINE
MAYTANSINE is a lipid of Polyketides (PK) class. Maytansine is associated with abnormalities such as Myelosuppression and BOSLEY-SALIH-ALORAINY SYNDROME. The involved functions are known as Mutation, Agent, Polymerization, Cell Cycle Arrest and Drug Kinetics. Maytansine often locates in Cytoplasm, Hepatic, Lysosomes, Cell surface and Microtubules. The associated genes with MAYTANSINE are ABCB1 gene, HM13 gene, CNN1 gene, CYP2C8 gene and CYP2D6 gene. The related lipids are Valerates. The related experimental models are Xenograft Model.
Cross Reference
Introduction
To understand associated biological information of MAYTANSINE, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with MAYTANSINE?
MAYTANSINE is suspected in Myelosuppression, BOSLEY-SALIH-ALORAINY SYNDROME and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with MAYTANSINE
PubChem Associated disorders and diseases
What pathways are associated with MAYTANSINE
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with MAYTANSINE?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with MAYTANSINE?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with MAYTANSINE?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with MAYTANSINE?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with MAYTANSINE?
Xenograft Model
Xenograft Model are used in the study 'IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.' (Ab O et al., 2015).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with MAYTANSINE
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Liang Y et al. | A Nanosystem of Amphiphilic Oligopeptide-Drug Conjugate Actualizing Both αvβ3 Targeting and Reduction-Triggered Release for Maytansinoid. | 2017 | Theranostics | pmid:28900511 |
| Khot A et al. | Development of a Translational Physiologically Based Pharmacokinetic Model for Antibody-Drug Conjugates: a Case Study with T-DM1. | 2017 | AAPS J | pmid:28808917 |
| Menderes G et al. | SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression. | 2017 | Clin. Cancer Res. | pmid:28679774 |
| Montemurro F | Trastuzumab emtansine in HER2-positive metastatic breast cancer. | 2017 | Lancet Oncol. | pmid:28526537 |
| Li C et al. | Exposure-response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane. | 2017 | Cancer Chemother. Pharmacol. | pmid:29022084 |
| Li C et al. | A Phase I Pharmacokinetic Study of Trastuzumab Emtansine (T-DM1) in Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function. | 2017 | Clin Pharmacokinet | pmid:27995530 |
| Cox K et al. | Emerging Therapeutic Strategies in Breast Cancer. | 2017 | South. Med. J. | pmid:28973703 |
| Kolodych S et al. | Development and evaluation of β-galactosidase-sensitive antibody-drug conjugates. | 2017 | Eur J Med Chem | pmid:28818506 |
| Du ZQ et al. | Combination of traditional mutation and metabolic engineering to enhance ansamitocin P-3 production in Actinosynnema pretiosum. | 2017 | Biotechnol. Bioeng. | pmid:28782796 |
| Kubizek F et al. | Status Quo in Antibody-Drug Conjugates - Can Glyco- Enzymes Solve the Current Challenges? | 2017 | Protein Pept. Lett. | pmid:28741467 |
| Menderes G et al. | Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression. | 2017 | Gynecol. Oncol. | pmid:28705408 |
| RÃos-Luci C et al. | Resistance to the Antibody-Drug Conjugate T-DM1 Is Based in a Reduction in Lysosomal Proteolytic Activity. | 2017 | Cancer Res. | pmid:28687619 |
| Harbeck N et al. | De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET. | 2017 | J. Clin. Oncol. | pmid:28682681 |
| Takegawa N et al. | DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance. | 2017 | Int. J. Cancer | pmid:28677116 |
| Mescher C et al. | Left Ventricular Ejection Fraction Screening and Clinical Decision-making in Metastatic HER2-positive Breast Cancer. | 2017 | Anticancer Res. | pmid:28668870 |
| Kmietowicz Z | NICE approves trastuzumab emtansine after deal with drug company. | 2017 | BMJ | pmid:28623237 |
| Krop IE et al. | Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. | 2017 | Lancet Oncol. | pmid:28526538 |
| Diéras V et al. | Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. | 2017 | Lancet Oncol. | pmid:28526536 |
| Morimura O et al. | Trastuzumab emtansine suppresses the growth of HER2-positive small-cell lung cancer in preclinical models. | 2017 | Biochem. Biophys. Res. Commun. | pmid:28526406 |
| Menderes G et al. | SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression. | 2017 | Gynecol. Oncol. | pmid:28473206 |
| Moore KN et al. | Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors. | 2017 | Cancer | pmid:28440955 |
| Ito K et al. | Near-Infrared Photochemoimmunotherapy by Photoactivatable Bifunctional Antibody-Drug Conjugates Targeting Human Epidermal Growth Factor Receptor 2 Positive Cancer. | 2017 | Bioconjug. Chem. | pmid:28402624 |
| Sun X et al. | Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates. | 2017 | Bioconjug. Chem. | pmid:28388844 |
| Eckelmann D et al. | Spatial profiling of maytansine during the germination process of Maytenus senegalensis seeds. | 2017 | Fitoterapia | pmid:28385670 |
| Diaby V et al. | Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives. | 2017 | Breast Cancer Res. Treat. | pmid:28840424 |
| Sabbaghi M et al. | Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer. | 2017 | Clin. Cancer Res. | pmid:28821558 |
| He X et al. | Inflammatory Monocytes Loading Protease-Sensitive Nanoparticles Enable Lung Metastasis Targeting and Intelligent Drug Release for Anti-Metastasis Therapy. | 2017 | Nano Lett. | pmid:28758755 |
| Shafaee MN et al. | Skin Necrosis After Ado-Trastuzumab Emtansine Extravasation. | 2017 | J Oncol Pract | pmid:28678590 |
| Venkatesa P | NICE recommends routine NHS funding for Kadcyla. | 2017 | Lancet Oncol. | pmid:28648556 |
| Zhong P et al. | cRGD-installed docetaxel-loaded mertansine prodrug micelles: redox-triggered ratiometric dual drug release and targeted synergistic treatment of B16F10 melanoma. | 2017 | Nanotechnology | pmid:28574851 |
| Loibl S and Gianni L | HER2-positive breast cancer. | 2017 | Lancet | pmid:27939064 |
| Zhao M et al. | Effects of the Methylmalonyl-CoA Metabolic Pathway on Ansamitocin Production in Actinosynnema pretiosum. | 2017 | Appl. Biochem. Biotechnol. | pmid:27787765 |
| Ohashi K et al. | Trastuzumab Emtansine in HER2+ Recurrent Metastatic Non-Small-Cell Lung Cancer: Study Protocol. | 2017 | Clin Lung Cancer | pmid:27497829 |
| Tumey LN and Han S | ADME Considerations for the Development of Biopharmaceutical Conjugates Using Cleavable Linkers. | 2017 | Curr Top Med Chem | pmid:29357803 |
| Zhong P et al. | αβ integrin-targeted micellar mertansine prodrug effectively inhibits triple-negative breast cancer in vivo. | 2017 | Int J Nanomedicine | pmid:29138558 |
| Li Y et al. | EpCAM aptamer-functionalized polydopamine-coated mesoporous silica nanoparticles loaded with DM1 for targeted therapy in colorectal cancer. | 2017 | Int J Nanomedicine | pmid:28894364 |
| Chen SC et al. | Population pharmacokinetics and exposure-response of trastuzumab emtansine in advanced breast cancer previously treated with ≥2 HER2-targeted regimens. | 2017 | Br J Clin Pharmacol | pmid:28733983 |
| Iwamoto N et al. | LC-MS bioanalysis of Trastuzumab and released emtansine using nano-surface and molecular-orientation limited (nSMOL) proteolysis and liquid-liquid partition in plasma of Trastuzumab emtansine-treated breast cancer patients. | 2017 | J Pharm Biomed Anal | pmid:28648785 |
| Seidel K et al. | Synthesis of Magnetic-Nanoparticle/Ansamitocin Conjugates-Inductive Heating Leads to Decreased Cell Proliferation In Vitro and Attenuation Of Tumour Growth In Vivo. | 2017 | Chemistry | pmid:28585348 |
| Lynce F et al. | SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function. | 2017 | Oncologist | pmid:28314836 |
| Janjigian YY and Braghiroli MI | Current Progress in Human Epidermal Growth Factor Receptor 2 Targeted Therapies in Esophagogastric Cancer. | 2017 | Surg. Oncol. Clin. N. Am. | pmid:28279471 |
| Stefan N et al. | Highly Potent, Anthracycline-based Antibody-Drug Conjugates Generated by Enzymatic, Site-specific Conjugation. | 2017 | Mol. Cancer Ther. | pmid:28258164 |
| Wang H et al. | Albumin nanoparticle encapsulation of potent cytotoxic therapeutics shows sustained drug release and alleviates cancer drug toxicity. | 2017 | Chem. Commun. (Camb.) | pmid:28195282 |
| Ait-Oudhia S et al. | A Mechanism-Based PK/PD Model for Hematological Toxicities Induced by Antibody-Drug Conjugates. | 2017 | AAPS J | pmid:28646408 |
| Loebrich S et al. | Development and Characterization of a Neutralizing Anti-idiotype Antibody Against Mirvetuximab for Analysis of Clinical Samples. | 2017 | AAPS J | pmid:28534292 |
| Meng H et al. | A Smart Nano-Prodrug Platform with Reactive Drug Loading, Superb Stability, and Fast Responsive Drug Release for Targeted Cancer Therapy. | 2017 | Macromol Biosci | pmid:28464449 |
| Singh AP and Shah DK | Application of a PK-PD Modeling and Simulation-Based Strategy for Clinical Translation of Antibody-Drug Conjugates: a Case Study with Trastuzumab Emtansine (T-DM1). | 2017 | AAPS J | pmid:28374319 |
| Lin J and Zhong JJ | Proteomic studies on anti-tumor agent ansamitocin P-3 producer Actinosynnema pretiosum in response to ammonium and isobutanol. | 2017 | Bioprocess Biosyst Eng | pmid:28382459 |
| Altundag K | Radio-sensitising effect of T-DM1 should not be discarded for the efficacy of radiosurgery in the management of brain metastases in patients with HER2-positive metastatic breast cancer. | 2017 | J. Neurooncol. | pmid:28337582 |
| Sang H et al. | Conjugation site analysis of antibody-drug-conjugates (ADCs) by signature ion fingerprinting and normalized area quantitation approach using nano-liquid chromatography coupled to high resolution mass spectrometry. | 2017 | Anal. Chim. Acta | pmid:28088282 |